At the time of writing, BioNTech SE ADR [BNTX] stock is trading at $98.08, down -1.67%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BNTX shares have gain 1.84% over the last week, with a monthly amount drifted -6.40%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
BioNTech SE ADR [NASDAQ: BNTX] stock has seen the most recent analyst activity on June 05, 2025, when H.C. Wainwright reiterated its Buy rating and also boosted its price target to $145 from $134. Previously, Goldman started tracking the stock with Neutral rating on May 29, 2025, and set its price target to $110. On March 13, 2025, Citigroup initiated with a Buy rating and assigned a price target of $145 on the stock. Truist started tracking the stock assigning a Buy rating and suggested a price target of $172 on January 10, 2025. Wells Fargo initiated its recommendation with a Overweight and recommended $170 as its price target on December 11, 2024. BMO Capital Markets reiterated a Outperform rating for this stock on December 02, 2024. In a note dated November 19, 2024, Evercore ISI upgraded an Outperform rating on this stock and boosted its target price from $110 to $125.
For the past year, the stock price of BioNTech SE ADR fluctuated between $81.20 and $129.27. Currently, Wall Street analysts expect the stock to reach $127.8 within the next 12 months. BioNTech SE ADR [NASDAQ: BNTX] shares were valued at $98.08 at the most recent close of the market. An investor can expect a potential return of 30.3% based on the average BNTX price forecast.
Analyzing the BNTX fundamentals
According to BioNTech SE ADR [NASDAQ:BNTX], the company’s sales were 3.13B for trailing twelve months, which represents an 113.52% jump. Gross Profit Margin for this corporation currently stands at 0.8% with Operating Profit Margin at -0.3%, Pretax Profit Margin comes in at -0.13%, and Net Profit Margin reading is -0.12%. To continue investigating profitability, this company’s Return on Assets is posted at -0.02, Equity is -0.02 and Total Capital is -0.04. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 97.37 points at the first support level, and at 96.66 for the second support level. However, for the 1st resistance point, the stock is sitting at 99.04, and for the 2nd resistance point, it is at 100.00.
Ratios To Look Out For
It is important to note that BioNTech SE ADR [NASDAQ:BNTX] has a current ratio of 8.61. As well, the Quick Ratio is 8.48, while the Cash Ratio is 5.55. Considering the valuation of this stock, the price to sales ratio is 7.54, the price to book ratio is 1.09.
Transactions by insiders
Recent insider trading involved ATHOS KG, 10% Owner, that happened on Sep 05 ’25 when 0.5 million shares were purchased. Officer, Medine GmbH completed a deal on Aug 15 ’25 to buy 1.77 million shares. Meanwhile, Officer Tureci Ozlem bought 0.19 million shares on Aug 15 ’25.
